PTGS2 and colorectal carcinoma: In line with these mechanisms, we observed that celecoxib treatment of IFN-γ-stimulated CRC cells (SW480, RKO) reduces CD274 protein expression (and PTGS2) (Supplementary Fig. 10), supporting a functional link between COX-2 signaling and PD-L1 regulation in CRC.